SYMPHOGEN A/S - CVR: 10013267

2022, DKK

25.03.2024

Bruttoresultat

206''

Primær drift

38.707'

Årets resultat

49.113'

Aktiver

368''

Kortfristede aktiver

200''

Egenkapital

186''

Afkastningsgrad

11 %

Soliditetsgrad

51 %

Likviditetsgrad

247 %

Resultat

25.03.2024

Årsrapport	2022 25.03.2024	2021 29.03.2023	2020 18.01.2022	2019 03.06.2020	2018 03.06.2019
Nettoomsætning	471.468.000
Bruttoresultat	205.932.000
Resultat af primær drift	38.707.000	-378.186.000	-149.081.000	-434.295.000	-356.324.000
Indtægter af kapitalandele (tilknyttede og associerede)	0
Finansielle indtægter	993.000	50.426.000	27.024.000	40.858.000	13.361.000
Finansieringsomkostninger	-7.851.000	-125.408.000	-28.804.000	-26.035.000	-22.999.000
Andre finansielle omkostninger	0
Resultat før skat	31.849.000	-453.167.000	-150.860.000	-419.472.000	-365.962.000
Resultat	49.113.000	-447.721.000	-145.481.000	-414.940.000	-360.147.000
Forslag til udbytte	0

Aktiver

25.03.2024

Årsrapport	2022 25.03.2024	2021 29.03.2023	2020 18.01.2022	2019 03.06.2020	2018 03.06.2019
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	186.149.000	0	0	0	0
Likvider	13.929.000	132.020.000	496.144.000	695.065.000	64.271.000
Kortfristede aktiver	200.078.000	414.607.000	911.936.000	951.494.000	309.114.000
Immaterielle aktiver og goodwill	0	0	0	0	0
Finansielle anlægsaktiver	36.302.000
Materielle aktiver	131.822.000	173.383.000	45.738.000	52.971.000	46.925.000
Langfristede aktiver	168.124.000	209.223.000	83.908.000	172.543.000	53.605.000
Aktiver	368.202.000	623.831.000	995.844.000	1.124.036.000	362.719.000

Aktiver

25.03.2024

Passiver

25.03.2024

Årsrapport	2022 25.03.2024	2021 29.03.2023	2020 18.01.2022	2019 03.06.2020	2018 03.06.2019
Forslag til udbytte	0
Egenkapital	186.388.000	-657.508.000	-225.991.000	-90.430.000	232.094.000
Hensatte forpligtelser	0
Langfristet gæld til banker	0
Langfristede forpligtelser		505.883.000	850.776.000	719.845.000	1.208.000
Kortfristede forpligtelser		775.456.000	371.059.000	494.621.000	129.417.000
Leverandører af varer og tjenesteydelser	26.878.000
Kortfristede forpligtelser	81.136.000
Gældsforpligtelser	0
Forpligtelser	0	1.281.339.000	1.221.835.000	1.214.466.000	130.625.000
Passiver	368.202.000	623.831.000	995.844.000	1.124.036.000	362.719.000

Passiver

25.03.2024

Nøgletal

25.03.2024

Årsrapport	2022 25.03.2024	2021 29.03.2023	2020 18.01.2022	2019 03.06.2020	2018 03.06.2019
Afkastningsgrad	10,5 %	-60,6 %	-15,0 %	-38,6 %	-98,2 %
Dækningsgrad	43,7 %
Resultatgrad	10,4 %	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	26,3 %	68,1 %	64,4 %	458,9 %	-155,2 %
Payout-ratio	Na.
Gældsdæknings-nøgletal	493,0 %	-301,6 %	-517,6 %	-1.668,1 %	-1.549,3 %
Soliditestgrad	50,6 %	-105,4 %	-22,7 %	-8,0 %	64,0 %
Likviditetsgrad	246,6 %

Resultat

25.03.2024

Gæld

25.03.2024

Årsrapport

25.03.2024

Nyeste:01.10.2022- 30.09.2023(offentliggjort: 25.03.2024)

Oplysning om eventualaktiver:In accordance with IP sales agreement, the company may be entitled to future milestone payments. Refer to note 4. For contingent assets relating to tax loss carry forward refer to note 17.

Beretning

25.03.2024

Dato for ledelsens godkendelse af årsrapporten:2024-02-15

Beskrivelse af usikkerhed ved indregning eller måling:Symphogen is subject to income taxes regulation in Denmark. Considering the complexity, by nature, associated with transactions implying the transfer of intellectual property rights and the various estimates and judgements made in relation to such transactions, Symphogen has recognized a provision for uncertain tax positions of DKK 22 million as of September 30, 2023. Due to the uncertainties, the provision for uncertain tax positions may deviate from the actual obligation. Refer to note 17 in the financial statements.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Symphogen A/S for the financial year 1 October 2022 - 30 September 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Symphogens main activities relates to working as a research and development service provider under a Les Laboratoires Servier service agreement to provide new antibody discoveries, improved research technologies and new therapeutic modalities. Symphogen is the Antibody Center of Excellence in the Servier Group. We apply our highly efficient antibody platform and capabilities in the discovery and early development of differentiated antibody therapeutics. We were founded in 2000 and became part of the Servier Group in June 2020 to support Servier’s commitment to improve patient’s health and the R&D strategy within oncology and immune oncology. We work with antibodies, the human body’s natural defense system designed to resist and fight disease. Every day, we work with innovative scientific approaches to antibody therapies to overcome the biological mechanisms leading to cancer or immuno-inflammatory diseases. We are passionate about making discoveries that can have a major impact on the lives of patients and their families.